Prostaglandin-I.sub.2 derivatives
    1.
    发明授权
    Prostaglandin-I.sub.2 derivatives 失效
    前列腺素I2衍生物

    公开(公告)号:US4191694A

    公开(公告)日:1980-03-04

    申请号:US928126

    申请日:1978-07-26

    摘要: Prostane derivatives of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ;R.sub.2 is hydrogen, C.sub.1-10 alkyl, C.sub.4-10 cycloalkyl, C.sub.6-10 aryl, or a 5 or 6 membered heterocyclic ring having 1-3 hetero atoms selected from O, N and S;R.sub.3 is the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms;W is (a) an OH-substituted methylene group, (b) a ##STR2## wherein the OH-groups in (a) or (b) can be in the .alpha.- or .beta.-position, or (c) such a group wherein the H atom of the OH group is replaced by the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms or by a conventional etherifying OH-blocking group;R.sub.4 is OH or hydroxy whose H atom is replaced as defined for W; andR.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 each independently is hydrogen or alkyl of 1-5 carbon atoms; or R.sub.9 and R.sub.10 together represent a direct bond; and, when R.sub.11 is alkyl, R.sub.10 can also be chlorine;and, for a derivative wherein R.sub.2 is hydrogen, the salts thereof with physiologically compatible bases,have improved prostaglandin activity.

    摘要翻译: 其中R1为OR2或NHR3的式(Ⅰ)所示的前驱体衍生物; R2是氢,C1-10烷基,C4-10环烷基,C6-10芳基或具有1-3个选自O,N和S的杂原子的5或6元杂环; R3是1-15个碳原子的烃羧酸或磺酸的残基; W是(a)OH-取代的亚甲基,(b)其中(a)或(b)中的OH基可以是α或β-位,或(c)这样的基团 其中OH基团的H原子被1-15个碳原子的烃羧酸或磺酸的残基或通过常规的醚化OH-封闭基团取代; R4是OH或羟基,其H原子被替换为W定义; R 5,R 6,R 7,R 8,R 9,R 10和R 11各自独立地为氢或1-5个碳原子的烷基; 或R 9和R 10一起代表直接键; 当R 11为烷基时,R 10也可为氯; 并且对于其中R 2是氢的衍生物,其与生理上相容的碱的盐具有改善的前列腺素活性。

    5-Cyano-prostacyclin derivatives
    2.
    发明授权
    5-Cyano-prostacyclin derivatives 失效
    5-氰基前列环素衍生物

    公开(公告)号:US4219479A

    公开(公告)日:1980-08-26

    申请号:US963240

    申请日:1978-11-24

    CPC分类号: C07D307/937

    摘要: Stabilized prostacyclins having a wide range of pharmacological activity and long duration of such activity, have the formula ##STR1## wherein R.sub.1 is (a) OR.sub.3, wherein R.sub.3 is hydrogen, alkyl, cycloalkyl, aryl or a heterocyclic residue; or (b) NHR.sub.4 wherein R.sub.4 is an acid residue;B is straight-chain or branched alkylene of 2-10 carbon atoms;A is --CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH--, trans--CH.dbd.CH-- or --C.tbd.C--,W is free or functionally modified hydroxymethylene or free or functionally modified ##STR2## wherein the OH-group can be in the .alpha.- or .beta.-position; D and E together are a direct bond; orD is straight-chain or branched alkylene of 1-5 carbon atoms; andE is oxygen or sulfur or a direct bond,R.sub.2 is alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group; andR.sub.5 is free or functionally modified hydroxy; and when R.sub.3 is hydrogen, the salts thereof with physiologically compatible bases.

    摘要翻译: 具有广泛的药理活性和长时间的这种活性的稳定的前列环素具有下式(IMAGE),其中R1是(a)OR3,其中R3是氢,烷基,环烷基,芳基或杂环残基; 或(b)NHR 4,其中R 4是酸残基; B是2-10个碳原子的直链或支链亚烷基; A是-CH 2 -CH 2 - ,顺式-CH = CH-,反式-CH = CH-或-C 3BOND C-,W是游离或官能改性的羟基亚甲基或游离或官能改性的,其中OH-基团可以是 在alpha或beta位置; D和E一起是直接的债券; 或D是1-5个碳原子的直链或支链亚烷基; 并且E是氧或硫或直接键,R 2是烷基,环烷基,任选取代的芳基或杂环基; R5是游离或官能改性的羟基; 并且当R3是氢时,其盐与生理上相容的碱基。

    5-Cyano-prostacyclin derivatives and use as medicines
    5.
    发明授权
    5-Cyano-prostacyclin derivatives and use as medicines 失效
    5-Cyano-prostacyclin衍生物用作药物

    公开(公告)号:US4364950A

    公开(公告)日:1982-12-21

    申请号:US317621

    申请日:1981-11-02

    摘要: 5-cyano-prostacyclins of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ; R.sub.2 and R.sub.3 each independently is (a) H, (b) C.sub.1-10 -alkyl, (c) C.sub.1-10 -alkyl substituted by halo, C.sub.1-4 -alkoxy or phenyl, 1-naphthyl or 2-naphthyl, each optionally substituted as defined below, (d) C.sub.4-10 -cycloalkyl, (e) C.sub.4-10 -cycloalkyl substituted by C.sub.1-4 -alkyl, (f) phenyl, 1-naphthyl or 2-naphthyl, (g) phenyl, 1-naphthyl or 2-naphthyl substituted by 1-3 halogen atoms, phenyl, 1-3 alkyl groups of 1-4 C atoms each, or a chloromethyl-, fluoromethyl-, trifluoromethyl-, carboxyl-, hydroxy- or alkoxy-group of 1-4 C atoms, or (h) an aromatic, 5- or 6-membered heterocyclic ring containing one hetero atom which is O, N or S, the remaining atoms being carbon; R.sub.3 also possibly being an acyl group of a C.sub.1-15 -hydrocarbon carboxylic or sulfonic acid;B is straight chain or branched alkylene of 2-10 C atoms;W is hydroxymethylene or ##STR2## wherein the OH group may be in the alpha or beta position, and is optionally modified by replacement of the H atom of the OH with an ether or acyl group which is conventional for such replacements in prostaglandins and which is readily cleavable at physiological pH's;R.sub.4 is hydroxy, optionally modified as described for W above;R.sub.5, R.sub.6, R.sub.7 and R.sub.8 each independently is hydrogen, alkyl of 1-5 C atoms or methoxy; andR.sub.9 is alkyl of 1-5 C atoms orfor compounds wherein R.sub.2 is H, the salts thereof with physiologically compatible bases have valuable pharmacalogical properties, e.g., hypertonic and bronchodilatory activities.

    摘要翻译: 其中R1是OR2或NHR3的式“IMAGE”的5-氰基 - 前列环素; R 2和R 3各自独立地为(a)H,(b)C 1-10 - 烷基,(c)被卤素,C 1-4 - 烷氧基或苯基,1-萘基或2-萘基取代的C 1-10 - 烷基, (d)C 4-10 - 环烷基,(e)被C 1-4 - 烷基取代的C 4-10 - 环烷基,(f)苯基,1-萘基或2-萘基,(g)苯基, 萘基或被1-3个卤素原子取代的2-萘基,苯基,1-4个C原子的1-3个烷基,或1个氯甲基 - ,氟甲基 - ,三氟甲基 - ,羧基 - ,羟基或烷氧基 -4个C原子,或(h)含有一个杂原子的芳族的5或6元杂环,它是O,N或S,其余的原子是碳; R3也可能是C1-15-烃羧酸或磺酸的酰基; B是2-10个C原子的直链或支链亚烷基; W是羟基亚甲基或其中OH基团可以在α或β位置,并且任选地通过用在前列腺素中这种替代物常规的醚或酰基取代OH的H原子来任意修饰,并且其是 在生理pH值下易于切割; R4是羟基,任选地按照上述W所述进行改性; R5,R6,R7和R8各自独立地为氢,1-5个C原子的烷基或甲氧基; 并且R 9为1-5个C原子的烷基,或对于其中R 2为H的化合物,其与生理上相容的碱的盐具有有价值的药理学性质,例如高渗和支气管扩张活性。

    Carbacyclins, process for the preparation thereof, and use thereof as
medicinal agents
    6.
    发明授权
    Carbacyclins, process for the preparation thereof, and use thereof as medicinal agents 失效
    卡巴菌素,其制备方法及其作为药剂的用途

    公开(公告)号:US5124343A

    公开(公告)日:1992-06-23

    申请号:US141233

    申请日:1988-01-06

    摘要: The invention relates to carbacyclins of general Formula I ##STR1## wherein R.sub.1 is the residue CH.sub.2 OH or ##STR2## with R.sub.2 meaning a hydrogen atom, an alkyl, cycloalkyl, aryl residue, a ##STR3## or heterocyclic residue, or R.sub.1 is the residue ##STR4## with R.sub.3 meaning an alkanoyl or alkanesulfonyl residue of respectively 1-10 carbon atoms or the residue R.sub.2, orR.sub.1 is the residue ##STR5## wherein m is the number 1 or 2, X is an oxygen atom or a CH.sub.2 -group,A is a trans--CH.dbd.CH- or --.tbd.C--group,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.- position,n is the number 1, 2, or 3,D is a straight-chain alkylene group of 1-5 carbon atoms,E is a --C.tbd.C---bond or a --CR.sub.6 =CR.sub.7 --group wherein R.sub.6 and R.sub.7 are different from each other and mean a hydrogen atom or an alkyl group of 1-5 carbon atoms or a hydrogen atom or a halogen atom, preferably chlorine,R.sub.4 is an alkyl, cycloalkyl, or optionally substituted arly group, or a heterocyclic group,R.sub.5 is a free or functionally modified hydroxy group, andif R.sub.2 means a hydrogen atom, the salts thereof with physiologically compatible bases;to processes for the preparation thereof, and to the use thereof as blood-pressure-lowering agents.

    摘要翻译: 本发明涉及通式I的碳霉素,其中R 1是残基CH 2 OH或R 2,其中R 2表示氢原子,烷基,环烷基,芳基,芳基或杂环残基,或者R 1是 残基其中R3表示分别为1-10个碳原子的烷酰基或烷磺酰基残基或残基R2,或R1为残基,其中m为数1或2,X为氧原子或CH2- 基团,A是反式-CH = CH-或 - 3BOND C-基团,W是游离或官能改性的羟基亚甲基基团,其中OH-基团可以是α或β位置,n是数1,2 或3,D是1-5个碳原子的直链亚烷基,E是-C3OND C键或-CR6 = CR7-基团,其中R6和R7彼此不同,意指氢 原子或1-5个碳原子的烷基或氢原子或卤素原子,优选氯,R4是烷基,环烷基或任选取代的芳基或杂环基团 p,R5是游离或功能改性的羟基,如果R 2表示氢原子,则其与生理上相容的碱的盐; 其制备方法及其作为降血压剂的用途。

    Novel prostacyclin derivatives and a process for the preparation thereof

    公开(公告)号:US4692464A

    公开(公告)日:1987-09-08

    申请号:US352411

    申请日:1982-02-26

    摘要: Compounds of the formula ##STR1## wherein R.sub.1 is (a) hydrogen, (b) C.sub.1-10 alkyl, (c) C.sub.1-10 alkyl substituted by halogen; C.sub.1-4 alkoxy; C.sub.6-10 aryl; C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group; di-C.sub.1-4 -alkylamino; or tri-C.sub.1-4 -alkylammonium, (d) C.sub.4-10 cycloalkyl, (e) C.sub.4-10 cycloalkyl substituted by C.sub.1-4 alkyl, (f) C.sub.6-10 aryl, (g) C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S;A is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C--;W is hydroxymethylene, RO-methylene, CH.sub.3 or CH.sub.3, ##STR2## wherein OH or OR is in the .alpha.- or .beta.-position and R is an in vivo hydrolyzable and physiologically acceptable ether or acyl group which is conventional for modifying OH groups in prostaglandins;D and E together are a direct bond, orD is C.sub.1-10 alkylene, C.sub.1-10 alkenylene or C.sub.1-10 alkynylene or one of these groups substituted by fluorine, andE is oxygen, --C.tbd.C-- or a direct bond;R.sub.2 is (a) a C.sub.1-10 hydrocarbon aliphatic radical, (b) a C.sub.6-10 hydrocarbon aliphatic radical substituted by C.sub.6-10 aryl or by C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group; (c) C.sub.4-10 cycloalkyl, (d) C.sub.4-10 cycloalkyl substituted by C.sub.1-4 alkyl, (e) C.sub.6-10 aryl, (f) C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group; or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S; andR.sub.3 is OH or OR; and, when R.sub.1 is hydrogen, the salts thereof with physiologically compatible bases, are effective as antihypertensive, bronchiodilators, thrombocyte aggregation inhibitors, inter alia.

    Crystalline prostanoic acid esters
    9.
    发明授权
    Crystalline prostanoic acid esters 失效
    结晶前列腺酸酯

    公开(公告)号:US4154953A

    公开(公告)日:1979-05-15

    申请号:US826908

    申请日:1977-08-19

    IPC分类号: C07C405/00 C07C177/00

    CPC分类号: C07C405/00

    摘要: Prostanoic acid esters of the formulaPG-- CH.sub.2 -- X-- Ywherein PG is the prostanoyloxy radical of a prostaglandin, X is a carbon-carbon single bond, carbonyl or carbonyloxy, and Y is substituted phenyl are easily crystallized compounds at least as active as the unesterified prostanoic acid and useful for the purification of the parent prostaglandin are prepared by reacting, in the presence of an agent which splits off hydrogen halide, the unesterified prostaglandin with a halide of the formula Hal--CH.sub.2 --X--Y, wherein Hal is a halogen atom and X and Y have the values given above.

    摘要翻译: 式PG-CH2-X-Y的前列腺酸,其中PG是前列腺素的前烷氧基自由基,X是碳 - 碳单键,羰基或羰氧基,Y是取代的苯基,容易结晶化合物至少与 通过使未分解的前列腺素与式Hal-CH2-XY的卤化物反应,其中Hal是卤素,其中Hal是卤素 原子,X和Y具有上面给出的值。